Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine’s SEC documents are packed with clinical data, trial endpoints and cash-burn tables that easily stretch beyond 200 pages. Finding where a Phase 2 read-out moved the needle or which executive exercised stock options can feel like searching for a gene variant in a genome.
Stock Titan solves that problem. Our AI parses every new 10-Q quarterly earnings report, 10-K annual report and 8-K material event the moment IRON files with EDGAR. Plain-language summaries surface R&D spend, milestone payments and risk factors, while real-time alerts flag Disc Medicine insider trading Form 4 transactions so you never miss a director’s buy or sell. Need to answer “How do I read Disc Medicine’s proxy statement executive compensation section?”—we highlight the exact tables in seconds.
Use the platform to:
- Track pipeline progress through 8-K trial disclosures explained simply
- Compare quarter-over-quarter cash runway with AI-annotated 10-Q trends
- Monitor Disc Medicine Form 4 insider transactions real-time for confidence signals
- Dive into “Disc Medicine annual report 10-K simplified” to spot hepcidin-pathway strategy updates
Whether you type “understanding Disc Medicine SEC documents with AI” into ChatGPT or ask Google for “Disc Medicine earnings report filing analysis,” this page delivers. Every filing, every footnote—decoded, searchable and always current.
Director Kevin Bitterman reported a series of open-market sales of Disc Medicine, Inc. common stock executed on
Form 144 notice indicates an intended sale of 71,961 shares of common stock by an affiliate, to be executed through Merrill Lynch on
Disc Medicine, Inc. (IRON) notice reports a proposed sale of 18,039 common shares with an aggregate market value of
Georges Gemayel, a director of Disc Medicine, Inc. (ticker: IRON), was granted a stock option to purchase 1,000 shares of common stock on 09/16/2025 at an exercise price of $60.34 per share. The option is exercisable subject to vesting that occurs on the earlier of the company’s 2026 annual meeting or the one-year anniversary of the grant date, and it expires on 09/15/2035. The filing reports the option as a direct holding and shows 1,000 underlying shares following the transaction.
This Form 4 was submitted by an attorney-in-fact and signed on behalf of the reporting person on 09/18/2025. No other transactions or cash sales are disclosed in the filing.
John D. Quisel, who serves as Chief Executive Officer and a director of Disc Medicine, Inc. (IRON), reported two related transactions dated 09/09/2025. He acquired 10,000 shares of common stock at $1.01 per share, bringing his total direct common stock holdings to 171,828 shares. On the same date he was granted or reported a stock option to buy 10,000 shares with an exercise price of $1.01, exercisable immediately and expiring 03/10/2030, increasing his total beneficial ownership including derivatives to 198,420 shares. The filing states the optioned shares are fully vested and exercisable as of the report date.
Kevin Bitterman, a director of Disc Medicine, Inc. (ticker: IRON), reported a sale of company stock under a pre-existing trading plan. On 08/22/2025 he sold 2,287 shares of common stock pursuant to a Rule 10b5-1 trading plan dated January 31, 2025, at a weighted average price of $61.03 per share (individual sale prices ranged from $60.95 to $61.05). The reporting person says he can provide a breakdown of shares sold at each price on request.
The report shows beneficial ownership held indirectly through Atlas-related investment vehicles: 590,621 shares in Atlas Venture Opportunity Fund I, LP; 420,549 shares in Atlas Venture Opportunity Fund II, LP; and 51,000 shares in Atlas Venture Fund XII, L.P. The filer disclaims beneficial ownership of those fund-held shares except to the extent of any pecuniary interest.
Form 144 filed for Disc Medicine, Inc. (IRON) reports a proposed sale of 2,287 shares of Common Stock through Merrill Lynch, with an aggregate market value of $136,648.25 and an approximate sale date of 08/22/2025 on Nasdaq. The shares were acquired in a private placement from the issuer on 05/01/2020 and paid in cash on that date. The filer reports no securities sold during the past three months for the account. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 plan adoption language.
Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 4,080 shares of common stock through Merrill Lynch, with an aggregate market value of $243,780.00. The filing shows the shares were acquired in a private placement from the issuer on 05/01/2020 and paid for in cash. The sale is scheduled to occur on or about 08/22/2025 and the shares are listed as traded on Nasdaq. The filer represents they are not aware of any undisclosed material adverse information about the issuer. No securities were reported sold by the filer in the past three months according to the form.
Disc Medicine director Kevin Bitterman reported sales of company common stock under a Rule 10b5-1 plan. The Form 4 shows sales on 08/13/2025 of 24,962 shares at a weighted-average price of $61.15 and on 08/14/2025 of 7,212 shares at a weighted-average price of $60.99, conducted pursuant to a 10b5-1 trading plan dated January 31, 2025. The filing lists substantial indirect holdings attributed to investment vehicles: 600,120 shares following the 08/13 sale and 592,908 shares following the 08/14 sale, plus additional holdings of 420,549 shares and 51,000 shares held by named funds. The report was signed by an attorney-in-fact on 08/15/2025.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
